1
|
Ciangola G, Gurnari C, Paterno G, Mirabile M, Angelini M, Lavorgna S, Ottone T, Travaglini S, Cicconi L, LoCoco F. Corrigendum to “STAT5b-RARa-positive acute myeloid leukemia: Diagnostic and therapeutic challenges of a rare AML subtype” [Leuk. Res. 78 (2019) 21–23]. Leuk Res 2020; 93:106148. [DOI: 10.1016/j.leukres.2019.04.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
2
|
Alfonso V, Iaccarino L, Ottone T, Cicconi L, Lavorgna S, Divona M, Cairoli R, Cristiano A, Ciardi C, Travaglini S, Falconi G, Hasan SK, Venditti A, Arcese W, Voso MT, Lo-Coco F. Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia. Leukemia 2019; 33:1527-1530. [PMID: 30651632 DOI: 10.1038/s41375-018-0298-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2018] [Accepted: 09/18/2018] [Indexed: 01/05/2023]
Affiliation(s)
- V Alfonso
- Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy
| | - L Iaccarino
- Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy
| | - T Ottone
- Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy.,Neuroimmunology and Flow Cytometry Units, Fondazione Santa Lucia-I.R.C.C.S, Rome, Italy
| | - L Cicconi
- Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy
| | - S Lavorgna
- Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy.,Neuroimmunology and Flow Cytometry Units, Fondazione Santa Lucia-I.R.C.C.S, Rome, Italy
| | - M Divona
- Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy
| | - R Cairoli
- Division of Hematology, Niguarda Hospital, Milan, Italy
| | - A Cristiano
- Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy
| | - C Ciardi
- Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy
| | - S Travaglini
- Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy
| | - G Falconi
- Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy
| | - S K Hasan
- CRI Lab 2, ACTREC, Homi Bhabha National Institute, Mumbai, India
| | - A Venditti
- Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy
| | - W Arcese
- Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy
| | - M T Voso
- Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy
| | - F Lo-Coco
- Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy. .,Neuroimmunology and Flow Cytometry Units, Fondazione Santa Lucia-I.R.C.C.S, Rome, Italy.
| |
Collapse
|
3
|
Cicconi L, Divona M, Ciardi C, Ottone T, Ferrantini A, Lavorgna S, Alfonso V, Paoloni F, Piciocchi A, Avvisati G, Ferrara F, Di Bona E, Albano F, Breccia M, Cerqui E, Sborgia M, Kropp MG, Santoro A, Levis A, Sica S, Amadori S, Voso MT, Mandelli F, Lo-Coco F. PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. Leukemia 2016; 30:1987-1992. [DOI: 10.1038/leu.2016.122] [Citation(s) in RCA: 59] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2016] [Revised: 04/05/2016] [Accepted: 04/12/2016] [Indexed: 11/09/2022]
|
4
|
Riva L, Ronchini C, Bodini M, Lo-Coco F, Lavorgna S, Ottone T, Martinelli G, Iacobucci I, Tarella C, Cignetti A, Volorio S, Bernard L, Russo A, Melloni GEM, Luzi L, Alcalay M, Dellino GI, Pelicci PG. Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups. Blood Cancer J 2014; 4:e195. [PMID: 24658373 PMCID: PMC3972704 DOI: 10.1038/bcj.2014.19] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
5
|
Riva L, Ronchini C, Bodini M, Lo-Coco F, Lavorgna S, Ottone T, Martinelli G, Iacobucci I, Tarella C, Cignetti A, Volorio S, Bernard L, Russo A, Melloni GEM, Luzi L, Alcalay M, Dellino GI, Pelicci PG. Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups. Blood Cancer J 2013; 3:e147. [PMID: 24036946 PMCID: PMC3789210 DOI: 10.1038/bcj.2013.46] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Affiliation(s)
- L Riva
- Center for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia, at the IFOM-IEO Campus, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Ammatuna E, Panetta P, Aguirre X, Ottone T, Lavorgna S, Lo Coco F, Calasanza M. 227 NPM1 gene abnormalities in myelodysplastic syndromes with long arm chromosome 5 deletion. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70229-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
7
|
Noguera NI, Ammatuna E, Zangrilli D, Lavorgna S, Divona M, Buccisano F, Amadori S, Mecucci C, Falini B, Lo-Coco F. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia 2005; 19:1479-82. [PMID: 15973451 DOI: 10.1038/sj.leu.2403846] [Citation(s) in RCA: 97] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Mutations in the Nucleophosmin (NPM1) gene have been recently described to occur in about one-third of acute myeloid leukemias (AML) and represent the most frequent genetic alteration currently known in this subset. These mutations generate an elongated NPM1 protein that localizes aberrantly in the cytoplasm. In analogy with Flt3 alterations, NPM1 mutations are mostly detectable in AML with normal karyotype and their recognition may be relevant to identify distinct response to treatment. Hence, in addition to conventional karyotyping and RT-PCR of fusion genes, combined analysis of both Flt3 and NPM1 mutations will be increasingly relevant in the genetic diagnosis work-up of AML. We developed a multiplex RT-PCR assay followed by capillary electrophoresis to simultaneously analyze NPM1 and Flt3 gene alterations (NFmPCR assay). The assay was validated in leukemic cell RNAs extracted from 38 AML patients, which had been previously characterized for Flt3 status by conventional RT-PCR. Direct sequencing of NPM1 RT-PCR products was carried out in 15 cases to verify results obtained by capillary electrophoresis. Both NPM1 sequencing and conventional RT-PCR Flt3 results showed 100% concordance with the results of the NFmPCR assay. We suggest that this assay may be introduced in routine analysis of genetic alterations in AML.
Collapse
Affiliation(s)
- N I Noguera
- Department of Biopathology, University of Tor Vergata, Rome, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Abdenur JE, Chamoles NA, Schenone AB, Jorge L, Guinle A, Bernard C, Levandovskiy V, Fusta M, Lavorgna S. Multiple acyl-CoA-dehydrogenase deficiency (MADD): use of acylcarnitines and fatty acids to monitor the response to dietary treatment. Pediatr Res 2001; 50:61-6. [PMID: 11420420 DOI: 10.1203/00006450-200107000-00013] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The treatment of multiple acyl-CoA-dehydrogenase deficiency (MADD) includes a low-fat, low-protein, high-carbohydrate diet, avoiding long fasting periods. However, there is no useful biochemical marker to determine the response to different diets or fasting periods. The aims of this study are to report a patient with MADD, diagnosed through a newborn screening program using tandem mass spectrometry, to assess her response to different feedings, and to evaluate the usefulness of acylcarnitines and FFA to monitor the response to dietary changes. The patient was diagnosed at 6 d. Family history revealed three dead siblings. Five tests were performed, one with breast milk and the subsequent four after giving the patient a bottle of a low-fat, low-protein formula (F), F with glucose polymers (GP), F+GP plus uncooked corn starch (CS), or F+GP+CS preceded by amylase. The results showed that acylcarnitines, FFA, and total nonesterified fatty acids levels were greatly improved at 2 and 4 h on F+GP compared with breast milk. At 6 mo of age, the test with F+CS was repeated to assess the response to a longer fast. The results were similar at 2 and 4 h, but showed a marked increase of acylcarnitines, FFA, and total nonesterified fatty acids at 6 h. The increase of these metabolites could not be avoided by the use of F+GP+CS, but was prevented when amylase was used simultaneously. The patient is currently 3.9 y old and has normal growth and development. We conclude that diagnosis of MADD through a newborn screening program using tandem mass spectrometry is suitable; acylcarnitines and FFA are useful to monitor the response to treatment; and exogenous amylase allows the use of CS in small children with MADD. This therapeutic approach may be an alternative to the use of continuous overnight feedings used for young children with severe fatty acid oxidation defects. Early diagnosis and treatment may change the natural history of MADD.
Collapse
Affiliation(s)
- J E Abdenur
- Fundación para el Estudio de las Enfermedades Neurometabólicas (F.E.S.E.N.), (1425) Uriarte 2383, Buenos Aires, Argentina.
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Abdenur JE, Chamoles NA, Specola N, Schenone AB, Jorge L, Guinle A, Bernard CI, Levandowskiy V, Lavorgna S. MCAD deficiency. Acylcarnitines (AC) by tandem mass spectrometry (MS-MS) are useful to monitor dietary treatment. Adv Exp Med Biol 2000; 466:353-63. [PMID: 10709663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
|